Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Shareholder Meeting (November 2020)
13 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 6, 2020
Slide 1: 2020 AGM Chairman's Address and CEO Presentation
ASX ANNOUNCEMENT 6 November 2020 2020 AGM Chairman’s Address and CEO Presentation For personal use only PYC Therapeutics Limited (the ‘Company’) submits the following Chairman’s Address and CEO Presentation to be made at the 2020 Annual General Meeting being held today at The Harry Perkins Institute
Slide 2: Chairman's Address
PYC Therapeutics Limited CHAIRMANS ADDRESS I am pleased to be able to report on another year of progress on several fronts: For personal use only Science – where significant advances were made - Further development of our lead program (VP001) addressing Retinitis Pigmentosa 11 with the goal of gaini
Slide 3: Life-changing science - Annual General Meeting November 2020
Life-changing science For personal use only Annual General Meeting November 2020
Slide 4: 2020 highlights
2020 highlights For personal use only PYC is an RNA therapeutics company specialising in diseases of the eye Major milestones achieved in 2020: 1 Lead program: PYC delivered the critical results demonstrating that its lead drug is capable of correcting the protein deficiency that causes Retinitis Pi
Slide 5: Financial position sees major milestones funded across each pipeline program
The strength of PYC’s financial position sees major milestones funded across each of the Company’s pipeline programs For personal use only PYC’s potential development pipeline in 2025 with successful completion of $55m raising Milestones (anticipated timing) Organ Program Discovery Pre-clinical IND-
Slide 6: 2021 a major catalyst for value creation in the lead RP11 program
2021 specifically is a major catalyst for value creation in the lead RP11 program For personal use only Anticipated 2021 milestones across major programs (1/4) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type 11 • Toxicology results in rabbi
Slide 7: Additional milestones in second and third development programs
Additional milestones will be realised in PYC’s second and third development programs For personal use only Anticipated 2021 milestones across major programs (2/4) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type 11 • PYC’s second and third
Slide 8: 2021 to mark introduction of first pipeline asset beyond the eye
2021 is anticipated to mark the introduction of PYC’s first pipeline asset beyond the eye For personal use only Anticipated 2021 milestones across major programs (3/4) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type 11 • The Central Nervous
Slide 9: Further value through progression of discovery programs to IP filing
Further value will be created through progression of discovery programs through to IP filing For personal use only Anticipated 2021 milestones across major programs (4/4) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type 11 PYC-001 Diabetic R
Slide 10: Successful delivery of 2021 objectives will move PYC beyond many peers
Successful delivery of these 2021 objectives will move PYC beyond many of its peers For personal use only Market Cap. USD M1 Cash, USD M2 Stage IND date Platform Lead target 380 4183 18 563 Pre-clinical 1H 22 RNA delivery Rare Ocular 1,070 345 Pre-clinical 2H 21 RNA delivery Rare Muscle 790 375 Pre-
Slide 11: Path to ensuring technical progress is mirrored in valuation
PYC has charted a path to ensuring that its technical progress is mirrored in the Company’s valuation For personal use only Value drivers Focus to ‘close the gap’ in 2021 1 Progress VP-001 to clinic Demonstrate safety in large animal toxicity studies 2 Scale PYC’s CPP-PMO Progress VEGF and OPA1
Slide 12: Realisation of 2021 milestones will make PYC leader in RNA therapeutics for the eye
Realisation of these milestones throughout 2021 will see PYC become the leader in RNA therapeutics for the eye For personal use only Success in 2021 will see PYC: • Eyeing first in human studies – PYC’s RP11 program will be about to enter a 36 month clinical development window prior to filing a New
Slide 13: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited trading as PYC Therapeutics Limited (ASX:PYC) (‘PYC’). These slides have been prepared as a presentation aid only and the information they contain may require further
PYC Therapeutics — Shareholder Meeting (November 2020) on 6ix